Miruvor
Sign up
The short answer

What studies of blue light therapy found

2papers on blue light therapy
43people in 1 study testing blue light therapy alone
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 2 of 3 findings are C.

3 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Blue light therapy might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 2 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Blue light therapy · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Fatigue1 study · 43 people received blue light therapy Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (43 in all).

Studies with no comparison group43 in the study · 10 full-body blue light irradiation for 15 min a day for 5 consecutive days each week (2 days of pause · 453 nm light (irradiance 40 mW/cm2), 15 min a day for 5 consecutive days each week (2 days of pause); 10 irradiations

Fatigue improved.

The evidence is very uncertain about the effect of blue light therapy on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (43 in all)
See the 1 study
  1. LED-emitted blue light improves quality of life and reduces fatigue after COVID-19 infection. (2024)

    People in the study
    43 in the study
    Dose
    453 nm light (irradiance 40 mW/cm2), 15 min a day for 5 consecutive days each week (2 days of pause); 10 irradiations
    Outcome
    Fatigue Severity Scale (FSS) Fatigue Severity Scale
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Autonomic symptoms1 study · 43 people received blue light therapy Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (43 in all).

Studies with no comparison group43 in the study · 10 full-body blue light irradiation for 15 min a day for 5 consecutive days each week (2 days of pause · 453 nm light (irradiance 40 mW/cm2), 15 min a day for 5 consecutive days each week (2 days of pause); 10 irradiations

No clear change in autonomic symptoms.

The evidence is very uncertain about the effect of blue light therapy on autonomic symptoms in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (43 in all)
See the 1 study
  1. LED-emitted blue light improves quality of life and reduces fatigue after COVID-19 infection. (2024)

    People in the study
    43 in the study
    Dose
    453 nm light (irradiance 40 mW/cm2), 15 min a day for 5 consecutive days each week (2 days of pause); 10 irradiations
    Outcome
    systolic blood pressure
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Quality of life1 study · 43 people received blue light therapy Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (43 in all).

Studies with no comparison group43 in the study · 10 full-body blue light irradiation for 15 min a day for 5 consecutive days each week (2 days of pause · 453 nm light (irradiance 40 mW/cm2), 15 min a day for 5 consecutive days each week (2 days of pause); 10 irradiations

Quality of life improved.

The evidence is very uncertain about the effect of blue light therapy on quality of life in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (43 in all)
See the 1 study
  1. LED-emitted blue light improves quality of life and reduces fatigue after COVID-19 infection. (2024)

    People in the study
    43 in the study
    Dose
    453 nm light (irradiance 40 mW/cm2), 15 min a day for 5 consecutive days each week (2 days of pause); 10 irradiations
    Outcome
    Dermatology Life Quality Index (DLQI) Dermatology Life Quality Index
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Side effects

No study of this treatment alone reported side effects we could read.

All papers

  1. LED-emitted blue light improves quality of life and reduces fatigue after COVID-19 infection.2024 · no comparison group · 43 in the study
    Summary

    This study enrolled 43 adults who had COVID-19 infection and reported a subjective feeling of fatigue 4 weeks after infection; participants were seen at the Dermatology, Paediatric Dermatology and Dermatological Oncology Clinic, Medical University of Lodz, Poland. All participants underwent 10 full-body blue light irradiations using Phlecs Full Body Blue 1.0 emitting 453 nm light (irradiance 40 mW/cm2) for 15 min a day for 5 consecutive days each week, with 2 days of pause. There was no comparison group; the authors state that another study with a placebo group is needed. Participants were assessed before starting and after the full irradiation regimen with the Fatigue Severity Scale (FSS), Short Form 36 Vitality Subscale (SF-36) and Dermatology Life Quality Index (DLQI); serum samples were taken from 20 individuals who provided additional consent. FSS decreased from 47.17 ±15.27 to 33.12 ±17.59 (p < 0.01), SF-36 increased from 57.10 ±27.67 to 76.07 ±25.77 (p < 0.01), and DLQI decreased from 7.62 ±6.49 to 3.95 ±5.02 (p < 0.01). Systolic blood pressure showed no significant change (p = 0.06), while diastolic blood pressure was significantly lower after 10 irradiations (from 81.2 to 78.5 mm Hg, p = 0.03). Harms and withdrawals were not reported. The authors state that patients should have been screened for depressive symptoms, that a placebo group is needed, and that more robust research with longer duration and larger group sizes is necessary.

  2. Chronic Fatigue Syndrome: A Case Report Highlighting Diagnosing and Treatment Challenges and the Possibility of Jarisch-Herxheimer Reactions If High Infectious Loads Are Present.2021 · case report · 1 in the study
    Summary

    This case report described one patient with severe ME/CFS who presented to a rheumatologist’s office in August 2013 after becoming bedridden 4.5 years earlier. Over a 4-year period from September 2013 to August 2017, the patient received a changing protocol that included thyroid medications, antibiotics, antifungals, Hydroxychloroquine, colostrum, kelp, licorice root, fludrocortisone, EFT, EMDR, light therapy, and multiple herbs and supplements. No comparison group was reported. The report described function and symptoms over time. By the Spring of 2014 (~6 months after onset of treatment), she had improved enough to take a college course 1 day/week but was not well enough to drive. By February 2015 she was still predominantly housebound; she was doing better cognitively, but simple activity like walking was still too difficult on most days. She was back at the gym by April 2017 and going for walks daily. In August 2017 she was well enough to move out from her parents’ home and resume graduate school, and she had been stable for at least 6 months. Reported harms included Jarisch–Herxheimer reactions with severe joint and musculoskeletal pain, worsening fatigue, worsening cognitive function, migraines, and drops in blood pressure; doxycycline was discontinued. She also had severe reactions from all supplements, severe discomfort during EFT/EMDR sessions, and could not tolerate blue light more than 1–2 min without severe migraines. The authors stated it was not possible to determine whether improvements were mediated by treatments or spontaneous remission/placebo.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime